Abstract: The present invention relates to a subway vehicle electronic record system based on blockchain technology, which mainly includes business view module, record information maintenance module, statistical analysis module, record information management module, system management module, and blockchain foundation platform. The invention comprehensively makes use of blockchain, database and other technologies to normalize heterogeneous data of subway vehicle record.

Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as siRNAs, able to Inhibin Subunit Beta E (INHBE) gene expression. Also disclosed are pharmaceutical compositions that include INHBE RNAi agents and methods of use thereof. The INHBE RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the INHBE RNAi agents in vivo provides for inhibition of INHBE gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by INHBE gene expression, such as obesity, diabetes, liver inflammation, dyslipidemia, or metabolic disease.

Abstract: The present invention provides a method for managing heat-electric outputs of a high-proportion new energy system based on CSP-CHP combined energy supply, which belongs to the field of new energy system optimization and are used for solving the problems of insufficient flexibility of the high-proportion new energy system during the heating period and difficult consumption of renewable energy. The method includes: establishing a concentrating solar power (CSP) unit model and a combined heat and power (CHP) unit model based on the built structure; establishing a collaborative optimization model of the high-proportion new energy system based on the proposed unit models; acquiring relevant data of various units and renewable resource data; obtaining a sum of hourly electric power outputs and a sum of hourly heat outputs; and controlling a heat storage apparatus to store or output a certain amount of heat energy.

Abstract: A display substrate is provided to include: a base substrate including a display area and a peripheral area surrounding the display area; pixel units in array are in the display area; a driving module is in the peripheral area and is configured to provide electrical signals for the pixel units, to control the pixel units to operate; the driving module includes driving circuits each provided with a corresponding operating signal line group in the peripheral area; the signal line group includes at least two operating signal lines connected to the corresponding driving circuit, to provide electrical signals thereto; the at least two operating signal lines include first and second clock signal lines; the first clock signal lines for at least two driving circuits are a same first clock signal line; and/or the second clock signal lines for the at least two driving circuits are a same second clock signal line.

Abstract: The present invention discloses a preparation method of highly alkali-stable cationic polymers, including the following steps: placing a polymerization mixture comprising 1-R1-3-piperidinone or its salts or hydrate thereof and arene monomers in a first organic solvent, performing catalytic polycondensation by adding organic strong acids, and obtaining a polymer dispersion with piperidine moieties; slowly dropping the dispersion of the polymer with piperidine moieties into a first precipitant, and obtaining a polymer powder with piperidine moieties after drying; dissolving the polymer powder with piperidine moieties of in a second organic solvent, after adding the quaternization reagent, obtaining a cationic polymer solution.

Abstract: A method for fabricating a semiconductor device includes the steps of: forming a gate structure on a substrate; forming a source/drain region adjacent to the gate structure; performing a first cleaning process; performing a first rapid thermal anneal (RTA) process to remove oxygen cluster in the substrate; forming a metal layer on the source/drain region; and performing a second RTA process to transform the metal layer into a silicide layer.

Abstract: The present disclosure provides a two-stage cavitation generator for organic wastewater treatment, including a shrouded impeller, a stator, and a rotor. The shrouded impeller includes a front cover plate, blades, and a rear cover plate. Several blades are evenly distributed between the front cover plate and the rear cover plate. A working surface of the blade is an arc surface, and a back of the blade protrudes locally, so that a flow channel between the back of the blade and a working surface of its adjacent blade is narrowed locally, forming a throat structure. An outlet of the shrouded impeller is provided with the stator and the rotor, and the stator is located at an outer edge of the front cover plate and fixed on an inner wall of a volute. The rotor is mounted on the rear cover plate.

Abstract: A base station is provided, which is configured for cleaning a cleaning member to be cleaned of a cleaning robot. The base station includes a base station body, a sewage cavity, a sewage input channel, and a sewage output channel. The base station body is provided with a cleaning system configured to clean the cleaning member to be cleaned and discharge sewage generated by the cleaning system. The sewage cavity is configured to hold the sewage. The sewage input channel is communicated with the cleaning system and the sewage cavity, and is configured to allow the sewage generated by the cleaning system to be transferred to the sewage cavity. The sewage output channel is communicated with the sewage cavity and an outside of the base station, and the sewage output channel has a closed state and an open state.

Abstract: Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I), including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.

Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene expression. Also disclosed are pharmaceutical compositions that include PNPLA3 RNAi agents and methods of use thereof. The PNPLA3 RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the PNPLA3 RNAi agents in vivo provides for inhibition of PNPLA3 gene expression. The RNAi agents can be used in methods of treatment of PNPLA3-related diseases and disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hepatic fibrosis, and alcoholic or non-alcoholic liver diseases, including cirrhosis.

Abstract: A peripheral input device module is connectable to a main control device to provide electrical signal(s) in response to a user interaction. The input device comprises one or more thermo-formable non-metallic conductive sensing electrodes configured to provide electrical signal(s) in response to a change in capacitance between (i) a sensing portion of the respective sensing electrode and a conductive object, and/or (ii) a sensing portion of the respective sensing electrode and a sensing portion of another of the one or more sensing electrodes or another sensing portion of the respective sensing electrode. At least one of the sensing electrodes comprises one or more connector portions that form an electrical connector. Each connector portion is configured to electrically connect to a respective electrical contact of a capacitive sensing circuit of the main control device for measuring the electrical signals.

Abstract: Provided is a SIRP? variant and a fusion protein thereof, capable of specifically blocking interaction between CD47 protein and SIRP?, not causing coagulation reaction, and capable of inhibiting growth and/or proliferation of tumors or tumor cells.

Abstract: The present application relates to a bifunctional fusion protein, which includes a first binding domain that specifically binds to CLDN18.2, and a second binding domain that specifically binds to a CD47 protein, wherein the second binding domain has at least one of the following characteristics: (a) binding to a CD47 protein at 4×10?8M or a lower KD value; (b) specifically blocking the interaction between CD47 protein and SIRP?; (c) not causing a coagulation reaction; and (d) inhibiting the growth and/or proliferation of a tumor or tumor cells.

Abstract: Embodiments of this application provide a method for selecting a network, applied to an electronic device, the method including: receiving a redirect message, where the redirect message carries information about a first frequency: selecting, based on a signal parameter of the first frequency and a signal parameter of a prior frequency, a target frequency from the first frequency and the prior frequency; and redirecting to a cell at the target frequency. It can be seen that after receiving the redirect message, the electronic device selects, based on the signal parameter of the frequency carried in the redirect message and the signal parameter of the prior frequency, the target frequency to be redirected to. Compared with a manner of redirecting to a cell at the frequency carried in the redirect message, the method is more conducive to selecting a frequency at which a signal is better, and further redirecting to a network in which a signal is better.

Abstract: Embodiments of present invention provide a linear-drive pluggable optics (LPO) transceiver. The LPO transceiver includes a receiver path, which includes a receiver optical subassembly (ROSA) converting an input optical signal into an ingress electrical signal; and a linear transimpedance amplifier (TIA) with adjustable frequency transfer function (AFTF), the ingress electrical signal passing through the linear TIA to a host. The LPO transceiver also includes a transmitter path, which includes a linear driver with AFTF receiving an egress electrical signal from the host; and a transmitter optical subassembly (TOSA) converting the egress electrical signal from the linear driver to an output optical signal. A method of operating the LPO transceiver is also included.

Abstract: Described are RNAi agents, e.g., double stranded RNAi agents, for inhibiting patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene expression. Also disclosed are pharmaceutical compositions that include PNPLA3 RNAi agents and methods of use thereof. The PNPLA3 RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the PNPLA3 RNAi agents in vivo provides for inhibition of PNPLA3 gene expression. The RNAi agents can be used in methods of treatment of PNPLA3-related diseases and disorders, including non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), hepatic fibrosis, and alcoholic or non-alcoholic liver diseases, including cirrhosis.

Abstract: The present application discloses a communication method, a server, and a computer device. The communication method includes that a server establishes a connection and feeds back a display control in response to requests of a first terminal and a second terminal; then, the server feeds back function feedback information in response to a function request of the first terminal, and feeds back function feedback information in response to a menu request of the second terminal; and the servers presents multiple interface components and maintains and updates each interface component in response to management operation of a third user.

Abstract: The present application discloses a communication method, a terminal, a server, a communication system, a computer device and a medium. The communication method includes that a server establishes a connection and feeds back a display control in response to requests of a first terminal and a second terminal; then, the server feeds back function feedback information in response to a function request of the first terminal, and feeds back function feedback information in response to a menu request of the second terminal; and the servers presents multiple interface components and maintains and updates each interface component in response to management operation of a third user.

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a double homeobox 4 (DUX4) gene. The DUX4 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a DUX4 gene. Pharmaceutical compositions that include one or more DUX4 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described DUX4 RNAi agents to skeletal muscle cells in vivo, provides for inhibition of DUX4 gene expression and a reduction in DUX4 levels, which can provide a therapeutic benefit to subjects, including human subjects, suffering from certain skeletal muscle-related diseases or disorders including Facioscapulohumeral Muscular Dystrophy (FSID).

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a double homeobox 4 (DUX4) gene. The DUX4 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a DUX4 gene. Pharmaceutical compositions that include one or more DUX4 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described DUX4 RNAi agents to skeletal muscle cells in vivo, provides for inhibition of DUX4 gene expression and a reduction in DUX4 levels, which can provide a therapeutic benefit to subjects, including human subjects, suffering from certain skeletal muscle-related diseases or disorders including Facioscapulohumeral Muscular Dystrophy (FSHD).